Loading
ClearNote Health's long-running study collecting blood from people with cancer to build its multi-cancer detection test.
ClearNote Health multi-cancer epigenomics study (NCT03869814) is an observational study sponsored by ClearNote Health. It aims to employ genomic, epigenomic and proteomic methods to detect a cancer signal in the blood of people with solid tumours.
The registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 20,000 participants, a start on 5 April 2018 and primary completion expected on 13 June 2029.
Shares Avantect Multi-Cancer Detection Test, ClearNote Health, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Avantect Multi-Cancer Detection Test, ClearNote Health, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/